Target intelligence / Profile preview

E3 ubiquitin-protein ligase CBLL2 (CBLL2)

Target
CBLL2
Molecular classification
Enzyme, E3 ubiquitin ligase, RING-type zinc finger protein
01

Overview

E3 ubiquitin-protein ligase CBLL2 (CBLL2) is an enzyme that belongs to the zinc finger protein family, containing both a RING-type and a C2H2-type zinc finger domain. CBLL2 catalyzes the ubiquitination of substrate proteins, tagging them for degradation via the ubiquitin-proteasome system. It is expressed in multiple tissues with prominent localization in the testis, implicating a possible role in human sperm production and quality control. While E3 ubiquitin ligases as a family play a critical part in protein turnover, signal transduction, and cellular homeostasis, specific mechanistic details of CBLL2’s disease associations or therapeutic potential are less well-established but may include cancer and reproductive biology due to its enzyme class’s function. No direct drugs or clinical interventions currently target CBLL2 specifically, but E3 ligases are increasingly recognized as key therapeutic nodes in targeted protein degradation strategies.

Other names
Cbl proto-oncogene like 2ZNF645FLJ25735HAKAILCT138Cbl proto-oncogene-like protein 2RING-type E3 ubiquitin transferase ZNF645Zinc finger protein 645c-Cbl-like protein 2
02

Mechanism of action

Indirect enzyme inhibition or targeted protein degradation; general mechanisms for E3 ubiquitin ligase inhibitors or PROTACs, but none specific to CBLL2 are available

03

Biological functions

Ubiquitination (posttranslational modification)Protein degradation (proteasome pathway)Protein quality controlPotential role in sperm production and testis function
04

Disease associations

Cancer (general role of E3 ligases in cancer pathways and as proto-oncogenes)Possible male infertility (suggested by tissue localization and putative function in sperm)
05

Safety considerations

No CBLL2-specific safety concerns documented; however, inhibition or dysregulation of E3 ligases can affect proteostasis and potentially contribute to oncogenesis, neurodegeneration, or developmental defects depending on context
06

Interacting drugs

None specifically documented for CBLL2; E3 ligases as a class are targeted by PROTACs and protein degradation strategies, but no direct CBLL2-targeting small molecules or drugs are presently listed in major databases
07

Biomarkers

No direct or established biomarkers for patient selection or efficacy monitoring for CBLL2 currently known.

Beyond the preview

Go deeper on E3 ubiquitin-protein ligase CBLL2 (CBLL2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E3 ubiquitin-protein ligase CBLL2 (CBLL2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call